Aslan Pharma raises US$34m in fresh funding
Singapore
THE Republic's fledgling pharma ecosystem on Monday got a shot in the arm as biotech startup Aslan Pharmaceuticals announced it has raised US$34 million in Series C funding led by Accuron Technologies, a tech subsidiary of Temasek Holdings.
The proceeds, said Aslan, will be used to further accelerate clinical development of its pipeline of four novel therapeutic agents, all of which have the potential to treat tumour types "prevalent in Asia", such as gastric, bile duct and breast cancers.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Technology
Brokers’ take: DBS cuts Venture Corp price target after Q1 earnings miss
Garmin’s Q1 results beat on strong demand for fitness, auto products
Foxconn’s musical chairs sound like punk rock
US sets up board to advise on safe, secure use of AI
Regulate AI? How US, EU and China are going about It
Meta’s results are best viewed through rose-tinted AI glasses